A Master Protocol for the Multi-cohort, Open-label, Phase 1/2 Study of DCC-3009 in Participants with Gastrointestinal Stromal Tumor (GIST)
Latest Information Update: 28 Oct 2024
At a glance
- Drugs DCC 3009 (Primary) ; Antineoplastics
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Deciphera Pharmaceuticals
- 22 Oct 2024 Status changed from not yet recruiting to recruiting.
- 14 Oct 2024 New trial record